We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

SYSMEX-EUROPA

Sysmex Europe designs and produces laboratory and hematology diagnostic solutions, including instruments, reagents, c... read more Featured Products: More products

Download Mobile App




Test Developed to Predict Sepsis in Burns Patients

By LabMedica International staff writers
Posted on 13 Jul 2016
The diagnosis of sepsis represents a major clinical challenge as many classical diagnostic biomarkers are masked by the ongoing systemic inflammatory response syndrome following major burn injury.

A potentially life-saving new test has been developed that will allow clinicians to predict which burn victims will develop sepsis during their treatment. More...
The test uses just three biomarkers of neutrophil function on the day of injury and can determine which patients with major burn injuries are likely to become septic.

Scientists at the University of Birmingham (UK) recruited 63 consecutive patients with burns into prospective cohort study within 24 hours of their injury. Blood samples were collected at fixed intervals following injury from day 1until 12 months. Those patients who died during the study and those patients who were lost to follow-up were included in the analysis. The source of sepsis for each episode was made through prospective recording of adverse events during the study. Pneumonia and ventilator-associated pneumonia (VAP), urinary tract infection (UTI), and central line associated blood stream infection (CLABSI) were diagnosed according to the US Centres for Disease Control (CDC, Atalnta, GA, USA) criteria.

Whole blood cell counts were performed on EDTA anticoagulated blood using the Sysmex XN-1000 hematology analyzer (Sysmex UK, Milton Keynes, UK). The measurement of neutrophil phagocytosis and oxidative burst was performed using the commercially available PhagoTEST and Phago- BURST kits (BD Biosciences, Oxford, UK). Both assays, using 10,000 neutrophils, were analyzed on the BD Bioscience Accuri C6 flow cytometer. The investigators also prepared platelet-free plasma, analyzed plasma and serum cell free DNA (cfDNA), performed reat time quantative polymerase chain rections, Western Blots and fluorescent micrsocpy.

The scientists found that neutrophil function was reduced for 28 days postburn injury and to a greater degree in patients who developed sepsis, which was also characterized by elevated immature granulocyte counts (IG) counts. The combination of neutrophil phagocytic capacity, plasma cfDNA levels, and IG count at day one postinjury gave good discriminatory power for the identification of septic patients.

Janet M. Lord, PhD, FmedSci, who jointly led the study said, “Our data showed that IG count could accurately discriminate between septic and non-septic patients, even with the complications that systemic inflammatory response syndrome has caused for other potential biomarkers. In addition to this, when we used a combination of two or more of our biomarkers, the discriminatory power was further enhanced.” The study was published online in June 2016 in the journal Annals of Surgery.

Related Links:
University of Birmingham
US Centres for Disease Control
Sysmex
BD Biosciences

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Online QC Software
Acusera 24•7
Steam Sterilizer
Hi Vac II Line
HPV Molecular Test
BD Onclarity HPV Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A new study identifies distinct metabolomic signatures in maternal blood associated with both the timing and type of early birth (Image credit: iStock)

Maternal Blood Biomarkers Identify Risk of Preterm and Early-Term Birth

Preterm and early-term births can lead to lasting complications because vital organs continue to mature during the final weeks of pregnancy. Babies born too soon face increased risks of breathing difficulties,... Read more

Molecular Diagnostics

view channel
Image: Spatial profiling of muscle-invasive bladder cancer reveals how distinct tumor cell states are organized within individual tumors (Image Credit: Shutterstock)

Spatial Map Guides Treatment Selection in Muscle-Invasive Bladder Cancer

Muscle-invasive bladder cancer is clinically heterogeneous, with patients often responding very differently to therapy. Existing biomarkers do not fully explain these disparities, limiting precision treatment... Read more

Microbiology

view channel
Image: Burkholderia pseudomallei is a soil-dwelling bacterium that causes melioidosis, a severe and potentially fatal infection that remains difficult to diagnose (Image Credit: Gavin Koh/Wikimedia Commons, CC BY-SA 4.0)

Stronger Laboratory Services Support Timely Melioidosis Diagnosis Amid Global Spread

Melioidosis, a potentially fatal infection caused by Burkholderia pseudomallei, remains difficult to recognize because its symptoms can mimic tuberculosis and other illnesses. The disease is considered... Read more

Industry

view channel
Image

QIAGEN Enhances QIAcuity Platform with Gene Expression and Multiplexing Tools

QIAGEN (Venlo, Netherlands) has introduced additions to its QIAcuity dPCR ecosystem that focus on gene expression, expanded assay content, and workflow standardization for life sciences and biopharma users.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.